nephrogenic systemic fibrosis


Also found in: Acronyms, Wikipedia.

nephrogenic systemic fibrosis

A rare condition linked to gadolinium-based MRI contrast solutions—in particular Omniscan and OptiMARK, which have a linear non-ionic structure and more likely to release Gd3+ to tissue—characterised by fibrosis of skin, joints, eyes and internal organs, resulting in scleromyxedema/papular mucinosis-like histologic appearance, limitation of joint movement, kidney failure and, in extreme cases, systemic fibrosis affecting the lungs, heart and liver.
 
Prevention
Some protection may be provided by diethylene-triaminepentaacetic acid.
Mentioned in ?
References in periodicals archive ?
Nephrogenic systemic fibrosis and gadolinium-based contrast media: Updated ESUR Contrast Medium Safety Committee guidelines.
Nephrogenic systemic fibrosis manifests as rapidly progressive fibrosis characterized by the deposition of [CD34.
Nephrogenic fibrosing dermopathy (NFD) is marked by areas of tight, rigid skin and may progress to nephrogenic systemic fibrosis (NSF), which is associated with scarring of internal organs.
Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.
In 2007 the FDA issued its first boxed warning about the risk of nephrogenic systemic fibrosis associated with GBCA use.
The presence of infection at the time of magnetic resonance imaging using gadolinium contrast may predispose patients with renal failure to the development of nephrogenic systemic fibrosis, according to a hospital analysis of patients with NSF.
Although gadolinium has been widely used for several years, there is recent evidence that this agent plays a central role in the development of acute renal failure (ARF), nephrogenic fibrosing dermopathy (NFD) and nephrogenic systemic fibrosis (NSF).
Considered extremely safe for most patients, gadolinium contrast has been linked to development of nephrogenic systemic fibrosis in about 200 patients with renal disease.
To our knowledge, we report the first case of nephrogenic systemic fibrosis involving the breasts of a 61-year-old woman with end-stage renal disease, clinically mimicking inflammatory breast carcinoma.
In the last 3 years, revelations linking gadolinium-based contrast agents (GBCAs) and nephrogenic systemic fibrosis (NSF) have had a tremendous impact on the utilization of enhanced magnetic resonance imaging (MRI) in patients with kidney disease.
NFD is also known as nephrogenic systemic fibrosis as it may extend to connective tissue and extensive fibrosis of other organs, with the potential to be a fatal disease (Food and Drug Administration [FDA], 2007a).